| Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria VM Isabella, BN Ha, MJ Castillo, DJ Lubkowicz, SE Rowe, YA Millet, ... Nature biotechnology 36 (9), 857-864, 2018 | 531 | 2018 |
| Reprogramming Probiotic Lactobacillus reuteri as a Biosensor for Staphylococcus aureus Derived AIP-I Detection D Lubkowicz, CL Ho, IY Hwang, WS Yew, YS Lee, MW Chang ACS Synthetic Biology 7 (5), 1229-1237, 2018 | 81 | 2018 |
| Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip MT Nelson, MR Charbonneau, HG Coia, MJ Castillo, C Holt, ... Nature communications 12 (1), 2805, 2021 | 59 | 2021 |
| Transplantability of a circadian clock to a noncircadian organism AH Chen, D Lubkowicz, V Yeong, RL Chang, PA Silver Science advances 1 (5), e1500358, 2015 | 49 | 2015 |
| An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria D Lubkowicz, NG Horvath, MJ James, P Cantarella, L Renaud, ... Molecular Systems Biology 18 (3), e10539, 2022 | 34 | 2022 |
| The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers M Perreault, J Means, E Gerson, M James, S Cotton, CG Bergeron, ... Cell Host & Microbe 32 (3), 382-395. e10, 2024 | 15 | 2024 |
| Bacteria engineered to treat disorders in which oxalate is detrimental VM Isabella, D Lubkowicz, M James US Patent App. 17/792,030, 2023 | 2 | 2023 |
| Sa1654: ENGINEERING SYNTHETIC BIOTIC MEDICINES TO SECRETE HUMAN PROTEINS AND SHORT CHAIN FATTY ACIDS AS A VERSATILE PLATFORM TO TREAT INFLAMMATORY BOWEL DISEASE AZ Reeves, S Kolodziej, J Shu, CC Chao, J Means, C Monahan, ... Gastroenterology 162 (7), S-455, 2022 | 2 | 2022 |
| PD21-10 SAFETY AND TOLERABILITY OF AN OXALATE-CONSUMING SYNTHETIC BIOTIC MEDICINE: SYNB8802 IN HEALTHY VOLUNTEERS WITH INDUCED DIETARY HYPEROXALURIA M Puurunen, W Denney, S Searle, S Scalera, A Marsh, D Lubkowicz, ... Journal of Urology 206 (Supplement 3), e378, 2021 | 2 | 2021 |
| Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors D Lubkowicz, DL Hava, K Lewis, VM Isabella ACS Synthetic Biology 13 (4), 1077-1084, 2024 | 1 | 2024 |
| Activity of SYNB1353, an investigational methionine-consuming synthetic biotic medicine, in an acute nonhuman primate model of HOMOCYSTINURIA M Perreault, E Gerson, J Means, M James, M Jessel, T Moore, A Reeves, ... Molecular Genetics and Metabolism 135 (4), 292-293, 2022 | 1 | 2022 |
| Bacteria for the treatment of disorders D Falb, AB Fisher, VM Isabella, JW Kotula, D Lubkowicz, PF Miller, ... US Patent App. 18/512,389, 2024 | | 2024 |
| Microorganisms engineered to reduce hyperphenylalaninemia K Adolfsen, P Greisen, I Callihan, A Lawrence, J Spoonamore, J Koniecza, ... US Patent App. 18/270,102, 2024 | | 2024 |
| Bacteria to treat disorders D Falb, Y Millet, AB Fisher, VM Isabella, JW Kotula, D Lubkowicz, ... | | 2024 |
| Bacteria engineered to treat disorders in which oxalate is detrimental VM Isabella, D Lubkowicz, M James, C Kurtz US Patent App. 18/283,268, 2024 | | 2024 |
| Bacteria for the treatment of disorders D Falb, AB Fisher, VM Isabella, JW Kotula, D Lubkowicz, PF Miller, ... US Patent 11,879,123, 2024 | | 2024 |
| SYNB1353, A PROPOSED THERAPY FOR HOMOCYSTINURIA, LOWERS PLASMA METHIONINE AND HOMOCYSTEINE IN HEALTHY VOLUNTEERS EXPOSED TO A METHIONINE CHALLENGE N Sondheimer, D Lubkowicz, J Blasbalg, J Means, M McDonald, M James, ... Molecular Genetics and Metabolism 138 (3), 107492, 2023 | | 2023 |
| GASTROINTESTINAL METHIONINE METABOLISM WITH LIVE BIOTHERAPEUTICS SYNB1353 RESULTS IN IMPROVED PLASMA METHIONINE AND HOMOCYSTEINE LEVELS IN MICE AND NONHUMAN PRIMATES M Perreault, E Gerson, J Xu, C Hannigan, M James, J Means, ... Molecular Genetics and Metabolism 138 (3), 107468, 2023 | | 2023 |
| Engineered Escherichia coli Nissle 1917 for the prevention of uremic toxin accumulation in chronic kidney disease D Lubkowicz Northeastern University, 2023 | | 2023 |
| Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery: PO2026 M Puurunen, W Denney, MK Ndugga-Kabuye, A Marsh, D Lubkowicz, ... Journal of the American Society of Nephrology 32 (10S), 622, 2021 | | 2021 |
